CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Joshua Mandel-Brehm

Chief Executive Officer, CAMP4 Therapeutics

Search every verified Joshua Mandel-Brehm interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Joshua Mandel-Brehm, CEO of CAMP4 Therapeutics, discussed the company’s approach to RNA therapeutics in a June 2025 interview at BIO Boston. He described CAMP4 as using antisense oligonucleotides to increase gene expression, positioning it as the inverse of companies like Ionis and Alnylam, and noted that hundreds of diseases involve missing healthy protein. He also commented on the transition from private to public company, stating that being public offers access to a broader set of shareholders and requires earning credibility daily, with the share price serving as a daily scorecard. In an April 2024 appearance on the Builders podcast, Mandel-Brehm recounted his background and the company’s pivot to regulatory RNAs, including a decision to halt all ongoing projects in March to focus on this area when the company had about 35 employees and no data. He described the company’s work as operating at the intersection of technology and biology, drawing on research from co-founder Rick Young at the Whitehead Institute. He also shared his perspective on company culture, defining it as a set of actions and virtues rather than written values, and mentioned that CAMP4 conducts annual surveys to assess its culture.

Recent appearances

  • Josh Mandel-Brehm - CEO CAMP4 Therapeutics at BIO Boston 2025

    July 07, 2025 · 📺 The Biohub

    Josh Mandel-Brehm, CEO of CAMP4 Therapeutics In this episode, I sit down with Josh Mandel-Brehm, the CEO of CAMP4 — a company pioneering a completely new approach in RNA therapeutics: upregulating gene expression using antisense oligonucleotides (ASOs). Josh shares the journey from a 5-person team to a publicly traded company, and how CAMP4’s platform is unlocking treatment for diseases previously out of reach — particularly in rare genetic and CNS disorders. We dive into: — What makes CAMP4’s approach so different — How they’ve scaled in a challenging market — The transition from private t…

    Watch on YouTube ↗

  • Builders #32 w/ Josh Mandel-Brehm - Co-Founder & CEO @ CAMP4 Therapeutics | BIOS

    April 29, 2024 · 📺 BIOS

    Guest: Josh Mandel-Brehm - Co-Founder & CEO @ CAMP4 Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics. Mr. Mandel-Brehm was previously an entrepreneur partner with Polaris Partners and held key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for t…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →